{
  "id": 3106955,
  "title": "Small-molecule inhibitors shown to promote robust antitumor immunity",
  "url": "https://urgent.news/2026/08/24/small-molecule-inhibitors-shown-to-promote-robust-antitumor-immunity",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-24T20:40:10.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-small-molecule-inhibitors-shown-robust.html"
  },
  "original_language": "en",
  "account": "Purdue University researchers have developed a new series of small-molecule inhibitors that enhance antitumor immunity and could serve as anticancer agents. The lead researcher, Zhong-Yin Zhang, pioneered L-32, a quinolone-based inhibitor, which has shown potential in reducing tumor growth and boosting the effectiveness of previous derivatives. PTPN22, a protein tyrosine phosphatase, plays a crucial role in immune regulation, and mutations in this protein serve as risk factors for multiple autoimmune disorders. By inhibiting PTPN22 with small-molecule inhibitors, Zhang aims to stimulate both innate and adaptive immunity against tumor cells.\n\nDespite PTPN22's known roles in cancer immunity, it has been underexplored as a therapeutic target due to the lack of high-quality small-molecule inhibitors. Zhang's team addressed this gap by creating a novel strategy to develop potent and selective PTP inhibitors, targeting both the active site and nearby unique pockets of the protein. They identified L-32 from a collection of druglike small molecules and demonstrated its improved potency, selectivity, and cellular efficacy compared to earlier compounds. L-32 also boasts a more favorable pharmacokinetic profile and drug properties, including oral bioavailability.\n\nIn syngeneic MC38 tumor models, L-32 has proven superior to previous molecules in reducing tumor growth by promoting robust antitumor immunity, making it a promising lead molecule for novel anticancer agents targeting PTPN22. The next steps for Zhang's research involve optimizing L-32 and evaluating its efficacy in more challenging cancers, such as pancreatic and liver cancers, as well as those resistant to current immunotherapies.",
  "summary": "Researchers in Purdue University's College of Pharmacy have developed and validated a new series of small-molecule inhibitors that promote antitumor immunity and hold promise as anticancer agents.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}